Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is typically infiltrated by immune cells that influence the response to conventional therapies. 1, 2 In addition, growing tumors cause systemic immune dysregulation, including expansion of myeloid populations. 3 Finally, recovery from surgery results in a systemic wound healing response that can perturb peripheral immune populations. 4 We hypothesized that peripheral expansion of myeloid or T cells would reflect similar increases in the tumor microenvironment and that increased intratumoral T-cell levels and robust postoperative immune recovery would correlate with improved outcome.
Methods | We conducted a prospective cohort study of resectable PDAC to determine which immunologic variables are associated with improved prognosis. We restricted our analysis to adult patients (18-100 years of age) who underwent upfront resection for PDAC from June 14, 2010, to November 24, 2014. We excluded patients who received neoadjuvant therapy, had other histologic subtypes, or had palliative surgery only. Peripheral populations were quantified in blood drawn before incision on the day of surgery and on the first postoperative visit with quantitative flow cytometry. We evaluated levels of CD3 Postoperative peripheral blood analysis was complete for a total of 41 patients. Of these, only increasing monocyte count was associated with improved outcome (Table 2) , with improved sur- vival found with increasing CD4 + cell levels. Patients were also divided into groups with high (n = 26) and low (n = 27) levels of CD3 + using median expression as a cutoff. Median survival was 20.5 and 18.8 months, respectively, and the 5-year survival estimate was 18.0 months (95% CI, 6.0-35.1 months) and 5.56 months (95% CI, 0.5-2.6 months), respectively. A similar analysis was performed for those with high (n = 22) and low (n = 22) levels of postoperative circulating monocytes. Median survival was 25.3 and 21.6 months, respectively; 5-year estimate of survival, 21.3 months (95% CI, 4.7-45.9 months) and 9.5 months (95% CI, 0.9-31.1 months), respectively. Multivariate Cox proportional hazards regression was performed using clinicopathologic and immunohistochemical information. Initially, all variables significant on the univariate analysis were included, and subsequently nonsignificant variables were removed in a stepwise fashion until the final model was generated. American Joint Committee on Cancer stage, CD3 + tumor infiltrate, lymphovascular invasion, and postoperative circulating monocytes remained significant (Table 2) .
Discussion | Only a subgroup of patients with pancreatic cancer present with malignant neoplasms that are eligible for surgical resection, and these are skewed toward early-stage disease. Within our study population and within the immune cell types studied, preoperative analysis of peripheral lymphocytes was not associated with survival and was not reflective of the intratumoral immune infiltrate. However, higher levels of tumor-infiltrating CD3 + T cells and higher postoperative circulating levels of monocytes were associated with an improved prognosis. These data suggest that, although peripheral blood immunocytes do not reflect the immune environment of the tumor, consideration of the systemic immune response during recovery from resection may be of value. Our data suggest a possible role for the patient's immune response on the outcome of pancreatic tumor resection and that interventions that change the tumor immune environment and the systemic response in the postresection period could influence patient outcomes.
